13G Filing: Tangiers Global, Llc and Endonovo Therapeutics Inc. (ENDV)

Page 4 of 5 – SEC Filing

CUSIP No. 29272H201 13G Page 4 of 5 Pages
Item 4 Ownership
(a) Amount beneficially owned
19,059,779*
(b) Percent of class: 9.99%*
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote 19,059,779*
(ii) Shared power to vote or to direct the vote
(iii) Sole power to dispose or to direct the disposition of
19,059,779*
(iv) Shared power to dispose or to direct the disposition
of

*Tangiers has rights, under a Convertible Promissory Note,
to own an aggregate number of shares of the Issuer’s common stock, which, except for a contractual cap on the amount of
outstanding shares of the Issuer’s common stock that Tangiers may own, could exceed such a cap. Tangiers’s ownership
cap is 9.99%. Thus, the number of shares of the Issuer’s common stock beneficially owned by Tangiers as of the date of this
filing was 19,059,779* shares, as calculated in accordance with Rule 13d-3(d)(1) under the Securities Exchange Act of 1934, which
is 9.99% of the 190,788,582 shares that were outstanding on that date.

 

Item 5 Ownership of Five Percent or Less of a Class

If this
statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the following ¨

 

Item 6 Ownership of More Than Five Percent on Behalf
Of Another Person

 

Item 7 Identification and Classification of the
Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

 

Item 8 Identification and Classification of Members
of The Group

 

Item 9 Notice of Dissolution of Group

 

Item 10 Certification
(a) The following certification
shall be included if the statement is filed pursuant to §240.13d-l (b):

By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held
in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant
in any transaction having that purpose or effect.

(b) The following certification
shall be included if the statement is filed pursuant to §240.13d-l(c):

By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Follow Endonovo Therapeutics Inc. (LON:ENDV)